Upper Airway Cough Syndrome Treatment Guidelines

Introduction to UACS Treatment

The American College of Chest Physicians recommends using first-generation antihistamines such as dexbrompheniramine 6 mg or azatadine 1 mg combined with pseudoephedrine 120 mg (sustained-release) twice daily for UACS treatment 1.

Dexbrompheniramine 6 mg twice daily is a recommended regimen for UACS treatment 1.
Azatadine 1 mg twice daily is a recommended regimen for UACS treatment 1.
Brompheniramine 12 mg twice daily is a recommended regimen for UACS treatment 1.
Chlorpheniramine 4 mg four times daily is a recommended regimen for UACS treatment 1.

First-generation antihistamines work primarily through their anticholinergic properties, which reduce nasal secretions and limit inflammatory mediators that trigger the cough reflex 1.
Second-generation antihistamines like loratadine, fexofenadine, and cetirizine are ineffective for UACS treatment due to lack of anticholinergic activity 2.

Start with a first-generation antihistamine/decongestant combination as first-line treatment for UACS, even before extensive diagnostic workup 2.
Recommended regimens include dexbrompheniramine 6 mg + pseudoephedrine 120 mg (sustained-release) twice daily 1, 3.
Azatadine 1 mg + pseudoephedrine 120 mg (sustained-release) twice daily is also a recommended regimen 1, 3.

Begin with once-daily dosing at bedtime for several days before advancing to twice-daily dosing to minimize daytime sedation 1, 3.
Improvement typically occurs within days to 2 weeks of starting treatment 1, 3.

If treatment fails after 2 weeks, consider gastroesophageal reflux disease (GERD) as an alternative or coexisting cause 3.
GERD can present as isolated cough without typical reflux symptoms ("silent GERD") 2.
Empiric proton pump inhibitor therapy (omeprazole 20-40 mg twice daily before meals) for at least 8 weeks is recommended for GERD 3.

Avoid first-generation antihistamines in patients with symptomatic benign prostatic hypertrophy or urinary retention 1.
Avoid first-generation antihistamines in patients with narrow-angle glaucoma 1.
Monitor for anticholinergic side effects including dry mouth, constipation, urinary retention, and increased intraocular pressure 1, 3.
Warn patients about potential sedation and performance impairment, which can occur even without subjective awareness 1.

The American Academy of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as the most effective medication class for controlling symptoms of allergic rhinitis, including sneezing, itching, rhinorrhea, and nasal congestion, and should be considered as initial treatment or added to first-generation antihistamines 4, 5
Intranasal antihistamines, such as azelastine or olopatadine, provide clinically significant effects on nasal congestion with rapid onset of action, and are effective for mixed rhinitis 4, 5
Leukotriene receptor antagonists, such as montelukast, may be particularly useful in patients with both allergic rhinitis and asthma, and are less effective than intranasal corticosteroids but address both conditions 4, 5, 6

Topical nasal decongestants, such as oxymetazoline, are safer than oral decongestants for patients with hypertension, but must be strictly limited to ≤3 days to avoid rhinitis medicamentosa 4

The American College of Chest Physicians suggests a layered approach for patients with comorbidities, such as allergic rhinitis, asthma, and possible hypertension, starting with first-generation antihistamine monotherapy and adding intranasal corticosteroids or leukotriene receptor antagonists as needed 4, 5, 6